复方氨基酸-20AA治疗肝硬化并发肝性脑病临床研究

目的观察第四代高支链复方氨基酸-20AA注射液治疗肝硬化并发肝性脑病的疗效和安全性。方法49例肝硬化肝性脑病患者随机分成对照组23例、治疗组26例,两组均给予去除诱因、纠正电解质紊乱和酸碱失衡、乳果糖及保肝治疗。治疗组在对照组用药基础上加用复方氨基酸-20AA注射液(丰诺安)500mL.L-1,每日1次,共用10d。监测治疗前后神志、Karnofsky评分、血氨、血清白蛋白、丙氨酸转氨酶及总胆红素的变化。结果复方氨基酸-20AA注射液显著改善患者神志、Karnofsky评分、血氨、ALT和TBIL,但血清Alb改善两组间无统计学意义。两组患者均未发现严重不良反应。结论第四代高支链复方氨基酸-20AA注射液治疗肝硬化并发肝性脑病安全、有效。

Clinical control study of compound amino acid 20AA on treatment of hepatic encephalopathy in patients with liver cirrhosis

Objective To investigate efficacy and safety of the fourth-generation branched-chain amino acid（BCAA） compound injection in the treatment of hepatic encephalopathy（HE） in patients with liver cirrhosis. Methods 49 cases of HE in patients with liver cirrhosis were randomly divided into control group（23 cases）and treatment group（26 cases）, respectively. The two groups were given to remove the inducement, correct disturbance of electrolyte and retrieve acid-base balance, and lactulose treatment. Otherwise, treatment group was administrated compound amino acid injection 20AA 500mL ~ L-1 , once a day for 10d. Mind, Karnofsky Performance Status （ KPS ） scores, blood ammonia, serum albumin （ AIb ）, alanine aminotrans ferase（ALT） ,and total bilirubin（TBIL）were monitored before and after treatment. Results The compound amino acid injection 20AA ameliorated delirium, KPS scores, blood ammonia,ALT and TBIL, but there was no significant improvement for serum AIb in two groups（ P 〉 0.05 ）. Meanwhile, no serious adverse reactions were found in two groups. Conclusions The fourth-generation BCAA compound injection 20AA may be considered as an effective adjuvant method for treating hepatic encephalopathy.